RT Journal Article
SR Electronic
T1 Current approaches in treatment of triple-negative breast cancer
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 106
OP 116
DO 10.7497/j.issn.2095-3941.2015.0030
VO 12
IS 2
A1 Wahba, Hanan Ahmed
A1 El-Hadaad, Hend Ahmed
YR 2015
UL http://www.cancerbiomed.org/content/12/2/106.abstract
AB Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting.